Advertisement

Melanoma pp 515-534 | Cite as

Management of Locally and Regionally Recurrent Melanoma

  • Cristina O’Donoghue
  • Jonathan S. Zager
  • Vernon K. SondakEmail author
Reference work entry

Abstract

Locally and regionally recurrent melanoma is a recurrence at the site of primary disease, the regional draining lymph node basin, or in between, described as satellite or in-transit metastases. Close follow-up of melanoma patients is merited as most recurrence is diagnosed from a physical exam. Adjunct imaging is important to determine the extent of disease and to rule out distant metastases. The treatment options for locoregional recurrent melanoma include: surgery, intra-arterial regional therapy, intralesional and topical therapies, radiation and systemic therapies. Factors such as time to recurrence, previous treatments, patient age, recurrence size, location and number should be considered to determine the best treatment option or sequence of options. Patients with melanoma recurrence should be discussed in a multidisciplinary tumor board especially as treatment options continue to develop and evolve.

Keywords

Melanoma In-transit Satellitosis Intra-arterial therapy Isolated limb infusion Intralesional therapy 

References

  1. Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of Bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I–III melanoma (E1673). Cancer 100(8):1692–1698PubMedCrossRefPubMedCentralGoogle Scholar
  2. Agarwala SS, Thompson JF, Smithers BM, Ross MI, Coventry BJ, Minor DR et al (2010) Chemoablation of metastatic melanoma with rose bengal (PV-10). J Clin Oncol 28(15_suppl):8534CrossRefGoogle Scholar
  3. Agarwala SS, Thompson JF, Smithers BM, Ross MI, Scoggins CR, Coventry BJ et al (2014) Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02. J Clin Oncol 32(15_suppl):9027CrossRefGoogle Scholar
  4. Agarwala SS (2015) Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol 27(2):151–156PubMedPubMedCentralCrossRefGoogle Scholar
  5. Agarwala SS, Ross M Zager JS, Essner R, Shirai K, Smithers BM, Atkinson V, Wachter E (2017) Preliminary results of a Phase 1b/2 study of PV-10 and pembrolizumab in Stage IV melanoma. In: World Congress of Melanoma/Society for Melanoma Research Congress, Brisbane, 18 Oct 2017Google Scholar
  6. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT (2009) The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 115(24):5836–5844PubMedCrossRefPubMedCentralGoogle Scholar
  7. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP (2018) Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181–193PubMedCrossRefPubMedCentralGoogle Scholar
  8. Amin MD et al (2017) AJCC cancer staging manual, 8th edn. Springer, ChicagoCrossRefGoogle Scholar
  9. Aloia TA, Grubbs E, Onaitis M, Mosca PJ, Cheng T-Y, Seigler H et al (2005) Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 140(11):1115–1120PubMedCrossRefPubMedCentralGoogle Scholar
  10. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788PubMedCrossRefPubMedCentralGoogle Scholar
  11. Andtbacka RHI, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA et al (2016) Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 23(13):4169–4177PubMedPubMedCentralCrossRefGoogle Scholar
  12. Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M et al (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10(1):85PubMedPubMedCentralCrossRefGoogle Scholar
  13. Aukema TS, Valdés Olmos RA, Wouters MWJM, Klop WMC, Kroon BBR, Vogel WV et al (2010) Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. Ann Surg Oncol 17(10):2773–2778PubMedCrossRefPubMedCentralGoogle Scholar
  14. Balch CM, S-J S, Gershenwald JE, Thompson JF, Coit DG, Atkins MB et al (2013) Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20(12):3961–3968PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bartlett EK, Gupta M, Datta J, Gimotty PA, Guerry D, Xu X et al (2014) Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol 21(3):1016–1023PubMedPubMedCentralGoogle Scholar
  16. Bastiaannet E, Wobbes T, Hoekstra OS, EJvd J, Brouwers AH, Koelemij R et al (2009) Prospective comparison of [18F]Fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 27(28):4774–4780PubMedCrossRefPubMedCentralGoogle Scholar
  17. Beasley G, Tyler D (2015) In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol 22(2):358–360PubMedCrossRefPubMedCentralGoogle Scholar
  18. Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15(8):2195–2205PubMedCrossRefPubMedCentralGoogle Scholar
  19. Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ et al (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208(5):706–715PubMedCrossRefPubMedCentralGoogle Scholar
  20. Beasley GM, Speicher P, Sharma K, Seigler H, Salama A, Mosca P et al (2014) Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg 218(4):686–692PubMedCrossRefPubMedCentralGoogle Scholar
  21. Bedikian AY, Del Vecchio M (2008) Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 8(6):839–844PubMedCrossRefPubMedCentralGoogle Scholar
  22. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20(3):218–226PubMedPubMedCentralGoogle Scholar
  23. Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C (2000) Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma. Cancer 88(11):2534–2539PubMedCrossRefPubMedCentralGoogle Scholar
  24. Blum A, Schmid-Wendtner MH, Mauss-Kiefer V, Eberle JY, Kuchelmeister C, Dill-Muller D (2006) Ultrasound mapping of lymph node and subcutaneous metastases in patients with cutaneous melanoma: results of a prospective multicenter study. Dermatology (Basel, Switzerland) 212(1):47–52CrossRefGoogle Scholar
  25. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology (Basel, Switzerland) 205(2):135–138CrossRefGoogle Scholar
  26. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13(6):589–597PubMedCrossRefPubMedCentralGoogle Scholar
  27. Chai CY, Deneve JL, Beasley GM, Marzban SS, Chen YA, Rawal B et al (2012) A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 19(5):1637–1643PubMedCrossRefPubMedCentralGoogle Scholar
  28. Cohen MH, Elin RJ, Cohen BJ (1991) Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother 32(5):315–324PubMedCrossRefPubMedCentralGoogle Scholar
  29. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, et al (2018) NCCN guidelines insights. Melanoma, Version 2. 2018. Available from: https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
  30. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE et al (2006) Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106(9):2012–2020PubMedCrossRefPubMedCentralGoogle Scholar
  31. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25):4196–4201PubMedCrossRefPubMedCentralGoogle Scholar
  32. Coventry BJ, Chatterton B, Whitehead F, James C, Gill PG (2004) Sentinel lymph node dissection and lymphatic mapping for local subcutaneous recurrence in melanoma treatment: longer-term follow-up results. Ann Surg Oncol 11:203S–207SPubMedCrossRefPubMedCentralGoogle Scholar
  33. Creech O Jr, Krementz E, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616PubMedPubMedCentralCrossRefGoogle Scholar
  34. Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG (2007) Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 14(6):1934–1942PubMedCrossRefPubMedCentralGoogle Scholar
  35. Damian DL, Thompson JF (2007) Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol 56(5):869–871PubMedCrossRefPubMedCentralGoogle Scholar
  36. Damian DL, Saw RP, Thompson JF (2014) Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 109(4):308–313PubMedCrossRefPubMedCentralGoogle Scholar
  37. Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ et al (2013) Single institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg 79(5):476–482PubMedPubMedCentralGoogle Scholar
  38. Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF (2000) Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 88(5):1063–1071PubMedCrossRefPubMedCentralGoogle Scholar
  39. Dossett LA, Ben-Shabat I, Bagge RO, Zager JS (2016) Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol 23(7):2330–2335PubMedCrossRefPubMedCentralGoogle Scholar
  40. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6):756–764. discussion 64-5PubMedPubMedCentralCrossRefGoogle Scholar
  41. Eggermont AM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530PubMedCrossRefPubMedCentralGoogle Scholar
  42. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845–1855PubMedPubMedCentralCrossRefGoogle Scholar
  43. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782–789PubMedPubMedCentralCrossRefGoogle Scholar
  44. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376(23):2211–2222PubMedPubMedCentralCrossRefGoogle Scholar
  45. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012a) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114PubMedCrossRefPubMedCentralGoogle Scholar
  46. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al (2012b) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703PubMedPubMedCentralCrossRefGoogle Scholar
  47. Florin V, Desmedt E, Vercambre-Darras S, Mortier L (2012) Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Investig New Drugs 30(4):1641–1645CrossRefGoogle Scholar
  48. Fraker DL (1999) Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 36(11):842–908CrossRefGoogle Scholar
  49. Fraker DL (2004) Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options in Oncol 5(3):173–184CrossRefGoogle Scholar
  50. Fraker DL, Alexander HR, Andrich M, Rosenberg SA (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14(2):479–489PubMedCrossRefPubMedCentralGoogle Scholar
  51. Francken AB, Accortt NA, Shaw HM, Wiener M, S-J S, Hoekstra HJ et al (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15(5):1476–1484PubMedCrossRefPubMedCentralGoogle Scholar
  52. Gangi A, Zager JS (2017) The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf 16(2):265–269PubMedPubMedCentralGoogle Scholar
  53. Gimbel MI, Delman KA, Zager JS (2008) Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 15(3):225–232PubMedCrossRefPubMedCentralGoogle Scholar
  54. Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH et al (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor α and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 12(8):609–615PubMedCrossRefPubMedCentralGoogle Scholar
  55. Hodi FS, O’day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010(363):711–723CrossRefGoogle Scholar
  56. Hong NJL, Petrella T, Chan K (2015) Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. J Surg Oncol 111(4):423–430CrossRefGoogle Scholar
  57. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12(22):6737–6747PubMedCrossRefGoogle Scholar
  58. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF et al (2014) Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAF V600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 32(33):3697–3704PubMedPubMedCentralCrossRefGoogle Scholar
  59. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA (1996) Local recurrence in malignant melanoma: long-term results of the multinstitutional randomized surgical trial. Ann Surg Oncol 3(5):446–452PubMedCrossRefGoogle Scholar
  60. Kroon BB, Noorda EM, Vrouenraets BC, Nieweg OE (2002) Isolated limb perfusion for melanoma. J Surg Oncol 79(4):252–255PubMedCrossRefPubMedCentralGoogle Scholar
  61. Kroon HM, Moncrieff M, Kam PCA, Thompson JF (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15(11):3003PubMedCrossRefPubMedCentralGoogle Scholar
  62. Kroon HM, Lin DY, Kam PC, Thompson JF (2009) Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 115(9):1932–1940PubMedCrossRefPubMedCentralGoogle Scholar
  63. Kroon HM, Coventry BJ, Giles MH, Henderson MA, Speakman D, Wall M et al (2016) Australian multicenter study of isolated limb infusion for melanoma. Ann Surg Oncol 23(4):1096–1103PubMedCrossRefPubMedCentralGoogle Scholar
  64. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015(373):23–34CrossRefGoogle Scholar
  65. Lee CC, Faries MB, Wanek LA, Morton DL (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26(4):535–541PubMedCrossRefPubMedCentralGoogle Scholar
  66. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17(6):757–767PubMedCrossRefPubMedCentralGoogle Scholar
  67. Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH (1991) The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 126(12):1461–1468PubMedCrossRefPubMedCentralGoogle Scholar
  68. Lienard D, Eggermont A, Schraffordt KH, Kroon B, Rosenkaimer F, Autier P et al (1994) Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-Centre pilot study. Melanoma Res 4:21–26PubMedPubMedCentralGoogle Scholar
  69. Lienard D, Eggermont A, Koops HS, Kroon B, Towse G, Hiemstra S et al (1999) Isolated limb perfusion with tumour necrosis factor-[alpha] and melphalan with or without interferon-[gamma]; for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9(5):491–502PubMedCrossRefPubMedCentralGoogle Scholar
  70. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246PubMedCrossRefPubMedCentralGoogle Scholar
  71. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888PubMedCrossRefPubMedCentralGoogle Scholar
  72. Long GV, Dummer R, Ribas A, Puzanov I, Michielin O, VanderWalde A et al (2015) Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. Eur J Cancer 51:S722CrossRefGoogle Scholar
  73. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377(19):1813–1823PubMedCrossRefPubMedCentralGoogle Scholar
  74. Luu C, Khushalani NI, Zager JS (2016) Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther 16(12):1491–1499PubMedCrossRefPubMedCentralGoogle Scholar
  75. Macdonald J, Dueck AC, RJ G (2011) Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer 2:538–543PubMedPubMedCentralCrossRefGoogle Scholar
  76. McMasters KM, Chao C, Wong SL, Wrightson WR, Ross MI, Reintgen DS et al (2002) Interval sentinel lymph nodes in melanoma. Arch Surg 137(5):543–547; discussion 7-9PubMedCrossRefPubMedCentralGoogle Scholar
  77. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G et al (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147(1):62–70PubMedCrossRefPubMedCentralGoogle Scholar
  78. Möller MG, Lewis JM, Dessureault S, Zager JS (2008) Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperth 24(3):275–289CrossRefGoogle Scholar
  79. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG (2008) Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 15(8):2206–2214PubMedCrossRefPubMedCentralGoogle Scholar
  80. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ et al (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180(4):635PubMedPubMedCentralCrossRefGoogle Scholar
  81. Muilenburg DJ, Beasley GM, Thompson ZJ, Lee J-H, Tyler DS, Zager JS (2015) Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol 22(2):482–488PubMedCrossRefPubMedCentralGoogle Scholar
  82. Noorda E, Vrouenraets B, Nieweg O, Van Geel A, Eggermont A, Kroon B (2002) Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 9(10):968–974PubMedCrossRefPubMedCentralGoogle Scholar
  83. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139(11):1237–1242PubMedCrossRefPubMedCentralGoogle Scholar
  84. Norman J, Cruse CW, Espinosa C, Cox C, Berman C, Clark R et al (1991) Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 162(5):432–437PubMedCrossRefPubMedCentralGoogle Scholar
  85. O’Donoghue C, Danielle Hardman SS, Mullinax JE, Perez M, Naqvi SMH, Kim Y, Zager JS (2017a) Isolated limb infusion: a single-center experience with 200 infusions. In: Regional Cancer Therapies 12th International Symposium, SnowbirdGoogle Scholar
  86. O’Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH et al (2017b) Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol 24(13):3842–3849PubMedCrossRefPubMedCentralGoogle Scholar
  87. Pidhorecky I, Lee RJ, Proulx G, Kollmorgen DR, Jia C, Driscoll DL et al (2001) Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 8(2):109–115PubMedCrossRefPubMedCentralGoogle Scholar
  88. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L et al (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34(22):2619–2626PubMedCrossRefPubMedCentralGoogle Scholar
  89. Radny P, Caroli U, Bauer J, Paul T, Schlegel C, Eigentler T et al (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626PubMedPubMedCentralCrossRefGoogle Scholar
  90. Rashid OM, Sloot S, Zager JS (2014) Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 10(10):1355–1364PubMedCrossRefPubMedCentralGoogle Scholar
  91. Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R et al (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213(2):306–316PubMedPubMedCentralCrossRefGoogle Scholar
  92. Read RL, Stalley P, Thompson JF (2015a) The contemporary role of major amputation in the management of advanced limb melanoma. Ann Surg Oncol 22(12):4067–4072PubMedCrossRefPubMedCentralGoogle Scholar
  93. Read RL, Haydu L, Saw RPM, Quinn MJ, Shannon K, Spillane AJ et al (2015b) In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol 22(2):475–481CrossRefPubMedPubMedCentralGoogle Scholar
  94. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J et al (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24(7):1178–1187PubMedCrossRefPubMedCentralGoogle Scholar
  95. Ribas A, Puzanov I, Gajewski T, Long GV, Dummer R, Kirkwood JM et al (2015) A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. J Clin Oncol 33(15_suppl):TPS9081CrossRefGoogle Scholar
  96. Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A et al (2001) Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 15(3):218–223PubMedCrossRefPubMedCentralGoogle Scholar
  97. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39PubMedCrossRefPubMedCentralGoogle Scholar
  98. Robinson JC (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9(6):587–593PubMedCrossRefPubMedCentralGoogle Scholar
  99. Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR et al (2009) Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 16(9):2570–2578PubMedCrossRefPubMedCentralGoogle Scholar
  100. Sarnaik A, Crago G, Liu H, Kodumudi KN, Weber A, McCardle T et al (2014) Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol 32(15_suppl):9028CrossRefGoogle Scholar
  101. Schellinger PD, Meinck HM, Thron A (1999) Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol 44(3):275–281CrossRefGoogle Scholar
  102. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC et al (2004) Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Investig Dermatol 122(5):1266–1276PubMedCrossRefPubMedCentralGoogle Scholar
  103. Si Z, Hersey P, Coates AS (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6(3):247–255PubMedCrossRefPubMedCentralGoogle Scholar
  104. Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ et al (2016) BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res 26(1):83–87PubMedCrossRefPubMedCentralGoogle Scholar
  105. Solivetti F, Sidozzi ADL, Pirozzi G, Coscarella G, Brigida R, Eibenshutz L (2006) Sonographic evaluation of clinically occult in-transit and satellite metastases from cutaneous malignant melanoma. Radiol Med 111(5):702–708PubMedCrossRefPubMedCentralGoogle Scholar
  106. Sonneveld EJ, Vrouenraets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE et al (1996) Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 22(5):521–527PubMedCrossRefPubMedCentralGoogle Scholar
  107. Speicher PJ, Meriwether CH, Tyler DS (2015) Regional therapies for in-transit disease. Surg Oncol Clin N Am 24(2):309–322PubMedPubMedCentralCrossRefGoogle Scholar
  108. Squires MH III, Delman KA (2013) Current treatment of locoregional recurrence of melanoma. Curr Oncol Rep 15(5):465–472PubMedCrossRefPubMedCentralGoogle Scholar
  109. Statius Muller MG, van Leeuwen PA, van Diest PJ, Pijpers R, Nijveldt RJ, Vuylsteke RJ et al (2002) Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg 26(12):1405–1411PubMedCrossRefPubMedCentralGoogle Scholar
  110. Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW et al (2014) Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer 120(9):1369–1378PubMedCrossRefPubMedCentralGoogle Scholar
  111. Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE et al (2017) Regional radiation therapy impacts outcome for node-positive cutaneous melanoma. J Natl Compr Canc Netw 15(4):473–482PubMedCrossRefPubMedCentralGoogle Scholar
  112. Thompson JF, Kam PC (2004) Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 88(1):1–3PubMedCrossRefPubMedCentralGoogle Scholar
  113. Thompson J, Eksborg S, Kam P, Ingvar C, Yau D, Lai D et al (1996) Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 6(3):267–271PubMedCrossRefPubMedCentralGoogle Scholar
  114. Thompson JF, Kam PC, Waugh RC, Harman CR (eds) (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14:238–247Google Scholar
  115. Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18(6):405–411PubMedCrossRefPubMedCentralGoogle Scholar
  116. Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ et al (2015) Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 22(7):2135–2142PubMedCrossRefPubMedCentralGoogle Scholar
  117. Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, Reiter MJ et al (1995) Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antivir Res 28(3):253–264PubMedCrossRefPubMedCentralGoogle Scholar
  118. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A et al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83:247–257PubMedCrossRefPubMedCentralGoogle Scholar
  119. Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE et al (1999) Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 188(5):522–530PubMedCrossRefPubMedCentralGoogle Scholar
  120. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824–1835PubMedCrossRefPubMedCentralGoogle Scholar
  121. Wieberdink J, Benckhuysen C, Braat R, Van Slooten E, Olthuis G (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905–910PubMedCrossRefPubMedCentralGoogle Scholar
  122. Wong J, Chen YA, Fisher KJ, Zager JS (2013) Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 20(4):1121–1127PubMedPubMedCentralCrossRefGoogle Scholar
  123. Wong J, Chen YA, Fisher KJ, Beasley GM, Tyler DS, Zager JS (2014) Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. Ann Surg Oncol 21(2):650–655PubMedCrossRefPubMedCentralGoogle Scholar
  124. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129–142PubMedPubMedCentralCrossRefGoogle Scholar
  125. Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL (2003) Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 238(5):743–747PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Cristina O’Donoghue
    • 1
  • Jonathan S. Zager
    • 2
  • Vernon K. Sondak
    • 2
    Email author
  1. 1.Department of Surgery, Division of Surgical OncologyRush UniversityChicagoUSA
  2. 2.Department of Cutaneous OncologyMoffitt Cancer CenterTampaUSA

Section editors and affiliations

  • Keith T. Flaherty
    • 1
  • Boris C. Bastian
    • 2
  • Hensin Tsao
    • 3
    • 4
  • F. Stephen Hodi
    • 5
    • 6
  1. 1.Henri and Belinda Termeer Center for Targeted TherapiesMGH Cancer CenterBostonUSA
  2. 2.Departments of Dermatology and Pathology, Helen Diller Family Comprehensive Cancer CenterUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.AuburndaleUSA
  4. 4.Harvard-MIT Health Sciences and TechnologyCambridgeUSA
  5. 5.FraminghamUSA
  6. 6.Department of Medicine, Brigham and Women's HospitalDana-Farber Cancer InstituteBostonUSA

Personalised recommendations